Fed. Circ. Won't Eye Amgen Case But Disputes 'Sky Is Falling'
The full Federal Circuit on Monday refused to revisit a decision that invalidated two of Amgen's patents on its cholesterol medication Repatha, though a panel of judges disputed the drugmaker's "sky...To view the full article, register now.
Already a subscriber? Click here to view full article